Table 2. The sensitivity analyses of the study.
| Sensitivity analyses | No. of studies | HR (95% CI) | OR (95% CI) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. of studies | OS | No. of studies | PFS | No. of studies | ORR | No. of studies | DCR | No. of studies | Grade ≥3 AEs | |||
| Total studies | 5 | 4 | 0.74 (0.60, 0.92) | 5 | 0.79 (0.70, 0.89) | 5 | 2.34 (1.35, 4.04) | 3 | 1.52 (1.21, 1.91) | 3 | 0.76 (0.52-1.11) | |
| McDermott 2019 excluded | 4 | – | – | 4 | 0.78 (0.69, 0.88) | 4 | 2.73 (1.48, 5.01) | – | – | 2 | 0.75 (0.45, 1.26) | |
| Motzer 2019 excluded | 4 | 3 | 0.73 (0.55, 0.97) | 4 | 0.82 (0.73, 0.93) | 4 | 2.18 (1.08, 4.41) | 2 | 1.44 (1.04, 2.00) | 2 | 0.61 (0.48, 0.78) | |
| Rini-1 2019 excluded | 4 | 3 | 0.81 (0.69, 0.96) | 4 | 0.82 (0.73, 0.93) | 4 | 2.28 (1.07, 4.82) | 2 | 1.45 (1.04, 2.02) | – | – | |
| Rini-2 2019 excluded | 4 | 3 | 0.68 (0.56, 0.84) | 4 | 0.78 (0.67, 0.92) | 4 | 2.84 (1.75, 4.62) | 2 | 1.72 (1.37, 2.17) | 2 | 0.94 (0.72, 1.22) | |
| Xu 2017 excluded | 4 | 3 | 0.74 (0.53, 1.03) | 4 | 0.77 (0.67, 0.88) | 4 | 1.86 (1.10, 3.12) | – | – | – | – | |
AE, adverse effect; CI, confidence interval; DCR, disease control rate; HR, hazard ratio; No., number; OR, odds ratio; ORR, objective response rate; OS, overall survival; PFS, progression-free survival.